NordiQC Workshop in Diagnostic Immunohistochemistry

Culture & Congress Centre 2nd – 4th October 2019

AALBORG UNIVERSITY HOSPITAL

Welcome to Aalborg

Why External Quality Assessment (EQA)? Nordigc

 Staining patterns and quality varies between different laboratories - depending on the expertise and individual selection of reagents and methods

 Different antibodies, visualization systems, chromogenes, and platforms often give different results – who can decide what is right or wrong?

 Internal quality control will often not identify a poorly calibrated IHC system or varying quality of products giving insufficient or aberrant staining results

• External Quality Assessment objectively compares a large number of stains, reagents and protocols to identify optimal and suboptimal results and products


Nordic Immunohistochemical Quality Control




- International organization for quality assurance of IHC
- Founded 2003 by Nordic pathologists
- Independent, scientific, not-for-profit organisation
- Institute of Pathology, Aalborg University Hospital, DK
- General module: 3 runs/year
 15-18 different marker challenges
 Breast cancer IHC module: 2 runs/y
 HER-2, ER/PR, Ki67/E-Cad ...
- HER-2 ISH module: 2 runs/year
 - BRISH, FISH
- Companion module 2017-
 - PD-L1











IHC for PAX8 in two laboratories: Lab 1 (A/C): Optimal results in Fallopian tube and Renal clear cell carcinoma. Lab 2 (B/D): Insufficient result in same tissues, especially characterized by false negative reaction in the neoplastic cells of the Renal clear cell carcinoma.

Results - Run 56, C5

9-Jul-2019

The results for the runs 56 and C5 are now available on the website. Individual results can be seen after logging in.

All news

Events

NordiQC Workshop in Diagnostic Immunohistochemistry 2–4 Oct 2019: Aalborg, DK

6th Academy of Diagnostic Immunohistochemistry 9–11 Oct 2019: Krakow, Poland

4th NordiQC Conference on Applied Immunohistochemistry 2–5 Jun 2020: Aalborg, Denmark

Important dates

Run 57, B28, H16, C6 Protocol submission opens 1 Aug 2019 Protocol submission deadline 4 Sep 2019 Slide circulation 10 Sep 2019 Slide return deadline 11 Oct 2019 Publication of results 6 Dec 2019

Questions

Check out our <u>FAQ</u> (Frequently asked questions) or <u>contact us</u>

WWW.NORDIQC.ORG FREE ACCESS



Modify protocol ID 635, CDX2, run 48

	Staining platform	
Staining platform	Ventana Benchmark Ultra	~
	Primary antibody	
Primary antibody clone	Cell Marque (235-Rxx) - EPR2764Y	~
Lot number	1523802К	
Dilution factor : 1:400	400	
Diluent buffer	Dako - Antibody Diluent (K8006)	~
Incubation time (minutes)	32	
Incubation temperature (Celcius)	36	
E	Epitope Retrieval, HIER	
Epitope retrieval, HIER	● YES ○ NO	
Device	On Board / On Machine	~
HIER buffer	Ventana - Ultra CC1 (950-224)	\checkmark

HIER buffer	Ventana - Ultra CC1 (950-224)	\checkmark						
Efficient Heating Time (minutes)	48							
Max. heating temperature (Celcius)	99							
Epitope Retrieval, proteolysis								
Epitope retrieval, proteolysis	O YES ● NO							

Visualization system								
Visualization system	OptiView DAB IHC Detection Kit - 760-700	~						
Amplification	None	~						
Incubation time linker (minutes)	8							
Incubation time polymer (minutes)	8							
Incubation temperature (Celcius)	36							

Test material



Multi-tissue FFPE blocks

10% NBF 24-48 h (ASCO/CAP guidelines ...)

- Normal and clinically relevant tumour tissues
- Different levels of antigen expression
 - high, moderate, low, none

LEICA


2 unstained slides for each marker send to the participants1 stained slide returned for central assessment


Test material



The slide to be stained for **Bcl-6** comprised: 1-2. Tonsils, 24 h/48 h

- 3. Follicular lymphoma, grade I
- 4. Follicular lymphoma, grade II
- 5. Diffuse large B-cell lymphoma






Tissue selection:High Expressor

- - to confirm antibody
- Low Expressor
 - to ensure sensitivity
- No-Expressor
 - to ensure specificity

NORTH DENMARK REGION

Companion – PD-L1






Neg.

≥1%.

≥50%.

IHC reference tests: Ventana PD-L1 (SP263) PD-L1 IHC 22C3 Dako pharmDx, SK006 PD-L1 IHC 28-8 Dako pharmDx, SK005

9



Heterogeneity in PD-L1 expression¹

Four "dimensions":


- Two in the slide
- One extra for all new slides
- One for primary vs. metastatic

¹Munari et al. PD-L1 Expression Heterogeneity in Non–Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections. Journal of Thoracic Oncology Vol. 13 No. 8: 1113-1120





NordiQC assessment





- ~ 100 Runs ~ 400 tests
- ~ 100,000 slides =
- ~ 500,000 tissue sections
- ~ 5,000,000 data





PD-L1 Run C5 2019, LUNG: 176 labs



	Table 3. Assessment marks for IHC assays and antibodies run C5, PD-L1 (lung) IHC										
	CE-IVD / FDA approved PD-L1 assays	n 108.	Vendor		Optimal	Good	Borderline	Poor	Suff.1	Suff. OPS ²	
Lab	rmAb clone SP263, 740- 4907 ³	16	Ventana/Roche		12	2	2	-	88%	93%	
Lab. mod.:	rmAb clone SP263, 740- 4907⁴	1	Ventana/Roche	Stainer transfer	-	-	-		-	-	
42/108	rmAb clone SP263, 741 - 4905⁵	4	Ventana/Roche	lianoroi	2	2	-	-	-	-	
42/100	rmAb clone SP263, 790- 4905	48	Ventana/Roche		34	10	4	-	92%	92%	
	mAb clone 22C3 pharmDX, SK006 ⁶	24	Dako/Agilent		17	5	-	2	92%	92%	
	mAb clone 22C3 pharmDX, SK006 ⁷	9	Dako/Agilent	Stainer transfer	2	2	1	4	44%	-	
	mAb clone 22C3 pharmDX, GE006 ⁸	3	Dako/Agilent		3	-	-	-	-	-	
	rmAb clone 28-8 pharmDX, SK005°	3	Dako/Agilent		2	1	-	-	-	-	
LDTs: 68	Antibodies ¹⁰ for laboratory developed PD-L1 assays, concentrated antibodies	n 68	Vendor (incl. "RTU")	Protocol transfer	Optimal	Good	Borderline	Poor	Suff.1	Suff. OPS ²	
	mAb clone 22C3	42	Dako/Agilent		11	20	9	2	74%	74%	
	mAb clone E1L3N	5	Cell Signaling		1	4	-	-	100%	100%	
	rmAb CAL10	3 3	Biocare Zytomed System	S	3	1	-	2	67%	100%	
	rmAb clone 28-8	4	Abcam		1	2	-	1	-	-	
	rmAb clone ZR3	1 1 1 1	Cell Marque Zeta Corporation Nordic Biosite Gene Tech		1	-	-	3	-	-	
	rmAb clone QR1	1 1	Quartett Diagomics		1	-	-	1	-	-	
	rmAb BSR90	1	Nordic Biosite		1	-	-	-	-	-	

PD-L1 Run C5 2019, LUNG: 176 labs

LDTs:


68



	Table 3. Assessment marks for IHC assays and antibodies run C5, PD-L1 (lung) IHC									
	CE-IVD / FDA approved PD-L1 assays	n 108	Vendor		Optimal	Good	Borderline	Poor	Suff.1	Suff. OPS ²
Lab.	rmAb clone SP263, 740- 4907 ³	16	Ventana/Roche		12	2	2	-	88%	93%
	rmAb clone SP263, 740- 4907 ⁴	. 1	Ventana/Roche	Stainer transfer	-	-	-	1	-	-
mod.: 42/108	rmAb clone SP263, 741 - 4905⁵	4	Ventana/Roche	transisi	2	2	-	-	-	-
42/100	rmAb clone SP263, 790- 4905	48	Ventana/Roche		34	10	4	-	92%	92%

Laboratory developed, modified or tranferred protocols 110 = 63%

Antibodies ¹⁰ for laboratory developed PD-L1 assays, concentrated antibodies	n 68	Vendor (incl. "RTU")	Protocol transfer	Optimal	Good	Borderline	Poor	Suff.1	Suff. OPS ²
mAb clone 22C3	42	Dako/Agilent		11	20	9	2	74%	74%
mAb clone E1L3N	5	Cell Signaling		1	4	-	-	100%	100%
rmAb CAL10	3 3	Biocare Zytomed Systems	5	3	1	-	2	67%	100%
rmAb clone 28-8	4	Abcam		1	2	-	1	-	-
rmAb clone ZR3	1 1 1 1	Cell Marque Zeta Corporation Nordic Biosite Gene Tech		1	-	-	3	-	-
rmAb clone QR1	1 1	Quartett Diagomics		1	-	-	1	-	-
rmAb BSR90	1	Nordic Biosite		1	-	-	-	-	-





Assessing the immunohistochemical assay quality

- Based on "standard" processed circulated tissues
- Identifying optimal and insufficient results
 - Correlated to antibodies, protocols and stainer platforms
- Publishing general results
 - Website: www.nordiqc.org (assessments and protocols)
 - Scientific journals
- Giving directions for improvement
 - Individually tailored recommendations



Search: PD-L1

Epitope 🛊	Staining Platform	Clone name	Clone format \$\u00e9	Version date 🛊	View 🛊
PD-L1	Dako Autostainer Link 48 +	22C3	RTU	08 Feb 2017	PDF
PD-L1	Dako Autostainer Link 48 +	28-8	RTU	02 Jan 2017	PDF
PD-L1	Dako Autostainer Link 48 +	E1L3N	CONC *	01 Dec 2017	PDF
PD-L1	Dako Autostainer Link 48 +	28-8	RTU	04 Dec 2017	PDF
PD-L1	Dako Autostainer Link 48 +	22C3	RTU	27 Dec 2017	PDF
PD-L1	Dako Omnis	22C3	CONC *	12 Dec 2017	PDF
PD-L1	Dako Omnis	22C3	CONC *	02 Sep 2018	PDF
PD-L1	Leica BOND III	E1L3N	CONC *	27 Aug 2018	PDF
PD-L1	Ventana Benchmark Ultra	SP263	RTU	18 Jan 2017	PDF
PD-L1	Ventana Benchmark Ultra	SP263	RTU	20 Dec 2017	PDF
PD-L1	Ventana Benchmark Ultra	22C3	CONC *	13 Feb 2018	PDF
PD-L1	Ventana Benchmark Ultra	22C3	CONC *	22 Aug 2018	PDF
PD-L1	Ventana Benchmark XT	SP263	RTU	25 Aug 2017	PDF
Protocols g	giving optimal results for	each clone a	nd platform may b	e downloaded	for free

All protocols

* LDTs



Accurate PD-L1 Protocols for Non–Small Cell Lung Cancer can be Developed for Automated Staining Platforms With Clone 22C3

Rasmus Røge, MD,*† Mogens Vyberg, MD,*† and Søren Nielsen, HT*

(Appl Immunohistochem Mol Morphol 2017;25:381–385)

TABLE 1. Protocol Parameters for the PD-L1 IHC 22C3 pharmDx Kit and the Optimized Protocols

Platform	AS48 Dako Link, 22C3 pharmDx, SK006 Dako	Dako Omnis, 22C3 Concentrate, M3653 Dako	BenchMark Ultra, Ventana, 22C3 Concentrate, M3653 Dako	BOND III, Leica, 22C3 Concentrate, M3653 Dako
HIER conditions	20 min at 97°C in target retrieval solution low pH 6.1—off board in PT-Link	40 min at 97°C in target retrieval solution low pH 6.1	48 min at 99°C in cell conditioning 1, pH 8.5 950-224, Ventana	30 min at 100°C in epitope retrieval solution 2 pH 9.0 AR9640, Leica
Primary antibody conditions Detection system conditions	SK006, ready-to-useIncubation for 30 min at room temperatureSK006, ready-to-useIncubation for 30 min in linker and 30 min in polymer at room temperature	GV805, Dako M3653, 1:20* Incubation for 40 min at 22°C GV800/821, Dako Incubation for 30 min in linker and 30 min in polymer at 22°C	M3653, 1:40* Incubation for 64 min at 36°C 760-700, Ventana Incubation for 8 min in linker and 8 min in multimer at 36°C	M3653, 1:20* Incubation for 60 min at room temperature DS9800, Leica Incubation for 20 min in postblock and 20 min in polymer at room temperature
Chromogen conditions	SK006, ready-to-use Incubation for 2 × 5 min at room temperature	GV825, Dako Incubation for 2×5min at 22°C	760-700, Ventana	DS9800, Leica Incubation for 8 min at room temperature

*Diluted in antibody diluent K8006, Dako.

HIER indicates heat-induced epitope retrieval; IHC, immunohistochemistry; PD-L1, programmed death-ligand 1.



Modern Pathology https://doi.org/10.1038/s41379-019-0327-4 Published online: 05 August 2019

REVIEW ARTICLE

Consensus opinion among authors, not approved



CAP

"Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy

Emina Torlakovic^{1,2} · Hyun J. Lim² · Julien Adam³ · Penny Barnes⁴ · Gilbert Bigras⁵ · Anthony W. H. Chan⁶ · Carol C. Cheung^{7,8} · Jin-Haeng Chung⁹ · Christian Couture¹⁰ · Pierre O. Fiset ¹¹ · Daichi Fujimoto¹² · Gang Han¹³ · Fred R. Hirsch¹⁴ · Marius Ilie ¹⁵ · Diana Ionescu¹⁶ · Chao Li¹⁷ · Enrico Munari ¹⁸ · Katsuhiro Okuda¹⁹ · Marianne J. Ratcliffe²⁰ · David L. Rimm ²¹ · Catherine Ross²² · Rasmus Røge²³ · Andreas H. Scheel ²⁴ · Ross A. Soo²⁵ · Paul E. Swanson^{26,27} · Maria Tretiakova²⁶ · Ka F. To⁷ · Gilad W. Vainer²⁸ · Hangjun Wang²⁹ · Zhaolin Xu⁵ · Dirk Zielinski³⁰ · Ming-Sound Tsao^{7,8}

... when the testing laboratory is not able to use an Food and Drug Administration [FDA] approved companion diagnostic(s) for PD-L1 assessment for its specific clinical purpose(s), it is **better to develop a properly validated laboratory developed test** for the same purpose(s) as the original PD-L1 FDA-approved immunohistochemistry [IHC] companion diagnostic, than to replace the original PD-L1 FDA-approved IHC companion diagnostic with a another PD-L1 FDA-approved companion diagnostic that was developed for a different purpose.



Assessment Run 42 2014

Bcl-6 protein (Bcl-6) Recommended Bcl-6 control tissue

Recommended Bcl-6 protocols

Material

The slide to be stained for **Bcl-6** comprised:

1. Tonsil, 24h fixation, 2. Tonsil, 48h fixation*, 3. Follicular lymphoma grade I, 4. Follicular lymphoma grade II, 5. Diffuse large B-cell lymphoma, non-Germinal Centre B-cell type (DLBCL non-GCB), 6. DLBCL, GCB.

All tissues were fixed in 10% neutral buffered formalin.

Criteria for assessing a Bcl-6 staining as optimal included:

- A moderate to strong distinct nuclear staining reaction of virtually all normal germinal centre Bcells in the tonsil fixed 24h.
- An at least weak to moderate distinct nuclear staining reaction of the majority of the squamous epithelial cells in the tonsil fixed 24h.
- A moderate to strong distinct nuclear staining reaction of the neoplastic cells in the two follicular lymphomas.
- An at least weak to moderate nuclear staining reaction of the majority of the neoplastic cells in th DLBCL, GCB subtype, tissue core no. 6.
- No or only a nuclear staining reaction in dispersed neoplastic cells of the DLBCL, non-GCB subtype tissue core no. 5

* The tonsil fixed for 48h (tissue core no 2) was excluded from the assessment due to an aberrant inconsistent staining reaction in the circulated material.

Participation

Number of laboratories registered for Bcl-6, run 42	244
Number of laboratories returning slides	228 (93%)

Results

228 laboratories participated in this assessment. Of these, 168 (74%) achieved a sufficient mark (optimal or good). Table 1 summarizes the antibodies (Abs) used and assessment marks (see page 2).

The most frequent causes of insufficient staining reactions were:

- too low concentration of the primary antibody
- less successful performance of the mAb clone PG-B6p
- use of low sensitivity detection systems

Performance history

This was the third NordiQC assessment of Bcl-6. An increased pass rate was seen compared to the two previous runs 17, 2006 and 28, 2010 (see table 2).

Table 2. Proportion of sufficient results for Bcl-6 in the three NordiQC runs performed

	Run 17 2006	Run 28 2010	Run 42 2014
Participants, n=	69	132	228
Sufficient results	42%	48%	74%

Conclusion

The mAbs clones GI191E/A8, LN22 and PG-B6p could all be used to produce optimal staining results for Bcl-6. Irrespective of the clone applied, efficient HIER in alkaline buffer, use of a high sensitive detection system and careful calibration of the primary antibody were the most important prerequisites for an

AALBORG UNIVERSITY HOSPITAL

Open website

Table 1. Antibodies and assessment marks for Bcl-6, run 42

	anu a	ssessment marks for b	a o, run 4	2				
Concentrated antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	Suff OPS
mAb clone GI191E/A8	13 1 1	Cell Marque Immunologic Zytomed	6	8	0	1	93%	100%
mAb clone LN22	38 2 1 1 1	Leica/Novocastra DBS Biocare BioGenex Zeta Corporation	20	16	4	3	84%	100%
mAb clone PG-B6p	43 1 1	Dako DBS Thermo/Neomarkers	9	22	11	3	69%	86%
Ready-To-Use antibodies								
mAb clone GI191E/A8 760-4241	59	Ventana/Cell Marque	24	25	9	1	83%	84%
mAb clone GI191E/A8 227M-9x	1	Cell Marque	0	0	1	0	-	-
mAb clone LN22 PA0204	10	Leica/Novocastra	3	7	0	0	100%	100%
mAb clone LN22 PM410	1	Biocare	1	0	0	0	-	-
mAb clone LN22 MAD-00638QD	1	Master Diagnostica	0	1	0	0	-	-
mAb clone PG-B6p IR/IS625	44	Dako	4	17	21	2	48%	75%
mAb clone PG-B6p GA625	7	Dako	2	2	3	0	57%	75%
mAb PG-B6p MAD-004023QD	2	Master Diagnostica	0	1	1	0	-	-
Total	228		69	99	50	10	-	
Proportion			30%	44%	22%	4%	74%	

1) Proportion of sufficient stains (optimal or good)

Proportion of sufficient stains with optimal protocol settings only, see below.

Detailed analysis of Bcl-6, Run 42

The following protocol parameters were central to obtain optimal staining:

Concentrated antibodies

mAb clone GI191E/A8: Protocols with optimal results were all based on HIER using Cell Conditi (CC1; Ventana) (6/14)* as retrieval buffer. The mAb was typically diluted in the range of 1:50-1: depending on the total sensitivity of the protocol employed. Using these protocol settings 9 of 9 (laboratories produced a sufficient staining result (optimal or good).

* (number of optimal results/number of laboratories using this HIER buffer)

mAb clone LN22: Protocols with optimal results were all based on HIER using Target Retrieval So (TRS) pH 9 (3-in-1) (Dako) (2/2), CC1 (Ventana) (9/18) or Epitope Retrieval Solution 2 (BERS2; (9/11) as retrieval buffer. The mAb was typically diluted in the range of 1:25-1:200 depending or sensitivity of the protocol employed. Using these protocol settings 27 of 27 (100%) laboratories p a sufficient staining result.



PDF file e-mailed to participants with assessment marks and – when needed explanations and recommendations



A	sessment of ER, B24 - individual results Aalborg Sygehus (101)	
Epitope	ER	
Assessment	Optimal	
distribution in cells expected to l staining and preservation of ti http://www.nordiqc.org/epitope.pl	tted slides. In general, the assessment is based on staining intensity a e demonstrated, background staining, cross-reactivity, quality of count sue morphology. Specific criteria for each epitope are described b. , good, borderline or poor based on the following criteria:	er-
Good: The staining reaction is c settings may be optimized to ens	onsidered perfect or close to perfect in all of the included tissues. nsidered acceptable in all of the included tissues. However, the proto re improved sensitivity or higher signal-to-noise ratio.	

Borderline: staining reaction, false negative or false positive staining reaction of one of the included tissues. The protocol should be optimized.

Poor: The staining reaction is considered insufficient because of, e.g., false negative or false positive staining reactions of several of the included tissues. An optimization of the protocol is urgently needed.

Moderate or strong cross reaction (due to the character of the primary antibody) or other false positive staining reaction (e.g. due to endogenous biotin) is not compatible with an optimal result and will usually cause downgrading.

For stains assessed as borderline or poor, comments and recommendations are given to the protocols. Good stains may also be accompanied by comments if specific problems are identified.

Recommended protocols from each staining platform are available at the NordiQC homepage (http://www.nordigc.org/recommended.php) for comparison. Implementation of NordiQC recommended protocols as well as changes suggested in this letter must be tested carefully in your own laboratory before implementation into diagnostic work. NordiQC do not take any responsibility for consequences of changes in protocols or methods in your laboratory.

contact percont(c).	L III	wine runen				iginal s
Marker	CD23	CR	CyD1	Ki67	Podop	TTF1
Assessment:	Poor	Optimal	Optimal	Good	Good	Borderline
Comments to the protocol:	Faise negative	-	-	Excessive counterstain	Weak	Weak
Suggestions for improvement:	Consider change of primary Ab and Ncalibrate	-	-	-	-	Increase primary Ab conc. and/or prolong HIER

* Please read the epitope description and assessment summary carefully, as the choice of the Ab clone will influence the sensitivity and specificity.

Nordic immunohistochemical Quality Control

Virchows Arch (2016) 468:19–29 DOI 10.1007/s00428-015-1829-1

ANNUAL REVIEW ISSUE

Proficiency testing in immunohistochemistry—experiences from Nordic Immunohistochemical Quality Control (NordiQC)

Mogens Vyberg 1,2 · Søren Nielsen 1

Vyberg et al. BMC Health Services Research (2015) 15:352 DOI 10.1186/s12913-015-1018-6

Health Services Research

BMC

Open Access

CrossMark

 (\mathbf{n})

Immunohistochemical expression of HER2 in breast cancer: socioeconomic impact of inaccurate tests

Mogens Vyberg^{1*}, Søren Nielsen¹, Rasmus Røge¹, Beth Sheppard², Jim Ranger-Moore², Eric Walk², Juliane Gartemann³, Ulrich-Peter Rohr³ and Volker Teichgräber³

AALBORG UNIVERSITY HOSPITAL

RESEARCH ARTICLE








Free PMC Article




General module ~20,000 slides (~100.000 core sections)







Breast cancer module ~9,000 slides (~35,000 core sections)









Major causes of insufficient stains in $\sim 9,00$	00 slides
Less successful antibodies/RTUs	17 %
Inappropriate antibody dilution	20 %
Inappropriate epitope retrieval	27 %
Inappropriate detection kit	19 %
Other inappropriate lab. performance	17 %
Endogenous biotin reaction (EBR)	
Section drying-out after HIER	
Technical platform error	
••••	
Unexplained	










Lab. A

Lab. B

ER in ductal breast carcinoma







AALBORG UNIVERSITY HOSPITAL

False neg.

NORTH DENMARK REGION



Control: uterine cerv



©Nord1QC



©NordiQC

False neg.



Control: uterine cerv

Clone SP1/EP1/1D5 in 225 labs

©NordiQC

©Nordi90

AALBORG UNIVERSITY HOSPITAL

©Nord/QC

NordiOC

Clone 6F11 in 15/37 labs





Estrogen receptor Pass rate (optimal + good) by participant status

	New participants	'Old' participants
Run 10, 2004	57%	71%
Run B15, 2010	70%	86%
Run B19, 2015	51%	73%
Average	59%	77%








Uneven Staining in Automated Immunohistochemistry: Cold and Hot Zones and Implications for Immunohistochemical Analysis of Biopsy Specimens

Carol C. Cheung, MD, PhD, JD,*† Paul E. Swanson, MD,‡ Søren Nielsen, BMS,§ Mogens Vyberg, MD,§ and Emina E. Torlakovic, MD, PhD||

(Appl Immunohistochem Mol Morphol 2018;26:299–304)



Wednesday, October 2nd

09:15 - 10:00		Arrival and registration, coffee	_
10:00 - 10:25	25	Welcome – Introduction	MV
10:30 - 11:10	40	IHC principles:	ON
		The technical test approach – pre-analytical phase I	UN
11:15 – 11:55	40	IHC principles:	ON
		The technical test approach – pre-analytical phase II	UN
12:00 - 12:50	50	Lunch	
12.55 – 13:35	40	IHC principles:	MB
		The technical test approach - analytical phase I	IVID
13:40 - 14:20	40	IHC principles:	MB
		The technical test approach - analytical phase II	IVID
14:20 - 14.40	20	Coffee	
14.40 - 15:40	60	IHC principles:	SN
		The technical test approach – Tissue tool box for controls	SIN
15:45 – 16:00	15	Discussion – 'Bring your own questions'	MV
16.00 - 18.00		Social arrangement (drinks and snacks will be served)	



Thursday, October 3 rd				
08:30 - 09:20	50	The unknown primary tumour: IHC for diagnostic use		
09:25 – 09:55	30	The unknown primary tumour: Antibody selection, protocols and controls		
10:00 - 10:20	20	Coffee		
10:25 – 11:05	40	Lung cancer: IHC for diagnostic use		
11:10 - 11:40	30	Lung cancer: Antibody selection, protocols and controls		
11:45 – 12:25	40	Breast cancer: IHC for diagnostic use		
12:30 - 13:20	50	Lunch		
13:25 – 13:55	30	Breast cancer: Antibody selection, protocols and controls	RR	
14:00 - 14:40	40	Haematolymphoid neoplasms IHC for diagnostic use	SH	
14:40 - 15:00	20	Coffee		
15:00 - 15:40	40	Haematolymphoid neoplasms: Antibody selection,		
		protocols and controls		
15:40 - 16:00	20	Discussion – 'Bring your own questions'	MV	
18:30 -		Workshop dinner (Mortens Kro)		





Mølleå 4



Friday, October 4 th				
08:30 - 09:15	45	IHC double stains – overview, considerations and	MB	
		applications		
09:20 – 10:05	45	Immunocytochemistry; IHC on frozen sections –	ON	
		overview, considerations and applications		
10:10 - 10:30	20	Coffee		
10:30 - 11:10	40	IHC stainers – overview, pros and cons	SN	
11:15 – 11:45	30	Organizing IHC data	ON	
11:45 – 12:00	15	Discussion and evaluation	MV	
12:00 - 12:50		Lunch (on-site and to-go), departure		









Aalborg Harbour Front





Aalborg House of Music
















The challenge of immunohistochemistry



"Immunohistochemistry is technically complex, and no aspect of this complexity can be ignored, from the moment of collecting the specimen to issuance of the final report"



Clive Taylor, 2000

Welcome to Aalborg